ABSTRACT
The paper describes the authors' experience with the new Russian antituberculous agent isonicotinic acid hydrazide (INAH) used in postpartum female patients with different forms of active and inactive pulmonary tuberculosis. The study group comprised 20 puerperas with respiratory tuberculosis of different degrees who received fenazid in a dose of 0.5 g daily for 2-3 months for therapeutic and preventive purposes. The comparison group included 36 puerperas given isoniazid in a daily dose of 0.6 g. The effectiveness of fenazid in treating and preventing respiratory tuberculosis allowed the agent to be used in postpartum period and recommended if there are side effects of isoniazid and altered peripheral blood parameters.
Subject(s)
Isoniazid/therapeutic use , Lung/pathology , Postpartum Period , Pregnancy Complications, Infectious/epidemiology , Tuberculosis, Pulmonary , Adult , Female , Hemoglobins/metabolism , Humans , Pregnancy , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/epidemiology , Tuberculosis, Pulmonary/pathologySubject(s)
Antitubercular Agents/therapeutic use , Labor, Obstetric , Postpartum Period , Pregnancy Complications , Tuberculosis, Pulmonary , Algorithms , Antitubercular Agents/administration & dosage , Female , Humans , Pregnancy , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/physiopathologyABSTRACT
The paper shows the experience gained in the use of the new Russian antituberculous drug fenazid in patients with different forms of active pulmonary tuberculosis and with neuro- and angiotoxic reactions to isoniazid. The study group comprised 25 patients aged 23 to 70 years who received fenazid as tablets in a daily dose of 0.5 g for 2 months at the first stage of the basic course of chemotherapy. The control group including 24 patients of the same age was given the routine antituberculous chemotherapy regimen, including isoniazid. The use of fenazid permits adequate therapy in patients with poor isoniazid tolerance, which may recommend fenazid to individuals at high risk for adverse reactions as their prevention.
Subject(s)
Antitubercular Agents/adverse effects , Iron Chelating Agents/chemistry , Isoniazid/analogs & derivatives , Isoniazid/adverse effects , Organometallic Compounds/adverse effects , Tuberculosis, Pulmonary/drug therapy , Adult , Aged , Antitubercular Agents/administration & dosage , Female , Humans , Isoniazid/administration & dosage , Male , Middle Aged , Organometallic Compounds/administration & dosageABSTRACT
Enzyme immunoassay of the titer of antituberculosis antibodies (ATAb) from patients with pulmonary tuberculosis has indicated that their levels depend on the different characteristics of a specific process: the form of active tuberculosis, the extent of changes in the lung tissue, the presence of destruction and bacterial isolation, the type of specific inflammatory reaction, and the duration of the treatment performed. Whether there was a correlation of ATAb titers with skin tuberculin sensitivity the level was studied by the Mantoux test using 2 TE PPD-L. The time course of changes in ATAb titers in patients with pulmonary tuberculosis during the routine chemotherapy was analyzed.
